DENTSPLY SIRONA (NASDAQ:XRAY) Price Target Cut to $12.00 by Analysts at Wells Fargo & Company

DENTSPLY SIRONA (NASDAQ:XRAY) had its price target trimmed by Wells Fargo & Company from $15.00 to $12.00 in a research note released on Friday,Benzinga reports. The brokerage currently has an equal weight rating on the medical instruments supplier’s stock.

Other equities analysts have also issued research reports about the company. Evercore ISI cut their price target on DENTSPLY SIRONA from $17.00 to $13.00 and set an “in-line” rating for the company in a research note on Wednesday, October 8th. Needham & Company LLC restated a “hold” rating on shares of DENTSPLY SIRONA in a research report on Friday, September 26th. UBS Group reduced their target price on DENTSPLY SIRONA from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, October 28th. Stifel Nicolaus set a $13.00 price target on shares of DENTSPLY SIRONA in a research note on Thursday. Finally, Mizuho set a $13.00 price objective on shares of DENTSPLY SIRONA in a research report on Friday. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $16.42.

DENTSPLY SIRONA Stock Performance

NASDAQ:XRAY traded up $0.16 during trading hours on Friday, reaching $11.18. The company had a trading volume of 6,022,111 shares, compared to its average volume of 3,066,050. DENTSPLY SIRONA has a 1-year low of $10.69 and a 1-year high of $20.59. The firm has a market cap of $2.23 billion, a PE ratio of -2.36, a price-to-earnings-growth ratio of 0.81 and a beta of 1.00. The business’s 50 day moving average price is $12.98 and its 200-day moving average price is $14.47. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.69 and a quick ratio of 1.11.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.37 EPS for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.08). DENTSPLY SIRONA had a positive return on equity of 16.33% and a negative net margin of 25.85%.The firm had revenue of $904.00 million for the quarter, compared to analyst estimates of $900.33 million. During the same period in the previous year, the business earned $0.50 EPS. DENTSPLY SIRONA’s revenue for the quarter was down 4.9% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2025 guidance at 1.600-1.600 EPS. Research analysts forecast that DENTSPLY SIRONA will post 1.84 EPS for the current year.

Institutional Trading of DENTSPLY SIRONA

Hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC increased its holdings in shares of DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after purchasing an additional 6,970,086 shares during the last quarter. Norges Bank acquired a new position in DENTSPLY SIRONA during the second quarter worth $39,700,000. Goldman Sachs Group Inc. grew its holdings in DENTSPLY SIRONA by 827.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after buying an additional 2,172,343 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of DENTSPLY SIRONA by 11.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 13,961,759 shares of the medical instruments supplier’s stock worth $208,590,000 after acquiring an additional 1,412,517 shares during the last quarter. Finally, Ninety One UK Ltd purchased a new position in shares of DENTSPLY SIRONA during the 2nd quarter worth $18,418,000. Institutional investors and hedge funds own 95.70% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.